Media sera and Reagents- Cell culture Companies

Latest Media Sera and Reagents Companies Update

• 
  Oct 2023: A new business partnership between Vaxcyte and Lonza pertains to the worldwide production of broad-spectrum pneumococcal conjugate vaccines (PCVs). The new agreement, which builds on an earlier partnership, will allow Vaxcyte's PCV candidates, VAX-24 and VAX-31, to be commercialized globally for adult and pediatric populations. This arrangement backs Vaxcyte's plan to use Lonza's current infrastructure for clinical research and the impending adult VAX-24 launch in the US. Vaxcyte will have access to a specially designed manufacturing suite from Lonza as part of its Ibex Dedicate Biopark at its Visp, Switzerland, location. The suite will be utilized to create necessary parts for the PCV franchise owned by Vaxcyte. With VAX-24 nearing late-stage clinical studies, Vaxcyte's production facility will assist in meeting the long-term worldwide market demands for adults and children.

• 
  May 2023: Merck Life Science, a pharmaceutical firm, and the Department of Atomic Energy partnered to provide heavy water for five years. According to an official announcement, a deal between Merck's sister company Sigma Aldrich Chemicals and Heavy DAE's Heavy Water Board will allow for manufacturing of deuterium-labeled compounds (DLCs) and related value-added products. Private companies' local manufacture of DLCs will increase India's exports.

• PAN biotech(Germany)


• Sigma Aldrich (US)


• Thermofisher Scientific (US)


• General electric company (US)


• Biowest (France)


• Merck KGaA (Germany)


• Lonza AG (Switzerland)


• Hi-media Laboratories (India)


• VWR International


• PromoCell GmbH